Literature DB >> 33782544

In search of the optimal setting for statin trials in prostate cancer: the power of population-based studies.

Emma H Allott1,2, Emma L Craig1, Konrad H Stopsack3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2021        PMID： 33782544      PMCID： PMC9548323          DOI： 10.1038/s41391-021-00355-y

Source DB:  PubMed          Journal:  Prostate Cancer Prostatic Dis        ISSN： 1365-7852            Impact factor:   5.455


× No keyword cloud information.
  10 in total

1.  Oral simvastatin administration delays castration-resistant progression and reduces intratumoral steroidogenesis of LNCaP prostate cancer xenografts.

Authors:  J A Gordon; A Midha; A Szeitz; M Ghaffari; H H Adomat; Y Guo; T L Klassen; E S Guns; K M Wasan; M E Cox
Journal:  Prostate Cancer Prostatic Dis       Date:  2015-08-04       Impact factor: 5.554

2.  Postdiagnosis Statin Use and Mortality in Danish Patients With Prostate Cancer.

Authors:  Signe Benzon Larsen; Christian Dehlendorff; Charlotte Skriver; Susanne Oksbjerg Dalton; Christina Gade Jespersen; Michael Borre; Klaus Brasso; Mette Nørgaard; Christoffer Johansen; Henrik Toft Sørensen; Jesper Hallas; Søren Friis
Journal:  J Clin Oncol       Date:  2017-08-14       Impact factor: 44.544

3.  Statin Use and Prostate Cancer Survival in the Finnish Randomized Study of Screening for Prostate Cancer.

Authors:  Teemu J Murtola; Antti I Peltomaa; Kirsi Talala; Liisa Määttänen; Kimmo Taari; Teuvo L J Tammela; Anssi Auvinen
Journal:  Eur Urol Focus       Date:  2016-06-02

Review 4.  The current evidence on statin use and prostate cancer prevention: are we there yet?

Authors:  Mahmoud A Alfaqih; Emma H Allott; Robert J Hamilton; Michael R Freeman; Stephen J Freedland
Journal:  Nat Rev Urol       Date:  2016-10-25       Impact factor: 14.432

5.  Statin Use at the Time of Initiation of Androgen Deprivation Therapy and Time to Progression in Patients With Hormone-Sensitive Prostate Cancer.

Authors:  Lauren C Harshman; Xiaodong Wang; Mari Nakabayashi; Wanling Xie; Loana Valenca; Lillian Werner; Yongjiang Yu; Aaron M Kantoff; Christopher J Sweeney; Lorelei A Mucci; Mark Pomerantz; Gwo-Shu Mary Lee; Philip W Kantoff
Journal:  JAMA Oncol       Date:  2015-07       Impact factor: 31.777

6.  Atorvastatin Versus Placebo for Prostate Cancer Before Radical Prostatectomy-A Randomized, Double-blind, Placebo-controlled Clinical Trial.

Authors:  Teemu J Murtola; Heimo Syvälä; Teemu Tolonen; Mika Helminen; Jarno Riikonen; Juha Koskimäki; Tomi Pakarainen; Antti Kaipia; Taina Isotalo; Paula Kujala; Teuvo L J Tammela
Journal:  Eur Urol       Date:  2018-07-18       Impact factor: 20.096

7.  Atorvastatin and celecoxib in combination inhibits the progression of androgen-dependent LNCaP xenograft prostate tumors to androgen independence.

Authors:  Xi Zheng; Xiao-Xing Cui; Zhi Gao; Yang Zhao; Yong Lin; Weichung Joe Shih; Mou-Tuan Huang; Yue Liu; Arnold Rabson; Bandaru Reddy; Chung S Yang; Allan H Conney
Journal:  Cancer Prev Res (Phila)       Date:  2010-01

8.  Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth.

Authors:  R Bruce Montgomery; Elahe A Mostaghel; Robert Vessella; David L Hess; Thomas F Kalhorn; Celestia S Higano; Lawrence D True; Peter S Nelson
Journal:  Cancer Res       Date:  2008-06-01       Impact factor: 12.701

9.  The Association Between Statin Use and Outcomes in Patients Initiating Androgen Deprivation Therapy.

Authors:  Robert J Hamilton; Keyue Ding; Juanita M Crook; Christopher J O'Callaghan; Celestia S Higano; David P Dearnaley; Eric M Horwitz; S Larry Goldenberg; Mary K Gospodarowicz; Laurence Klotz
Journal:  Eur Urol       Date:  2020-12-31       Impact factor: 20.096

10.  Prostate cancer prognosis after initiation of androgen deprivation therapy among statin users. A population-based cohort study.

Authors:  A Auvinen; T J Murtola; A I Peltomaa; P Raittinen; K Talala; K Taari; T L J Tammela
Journal:  Prostate Cancer Prostatic Dis       Date:  2021-03-31       Impact factor: 5.554
  10 in total
  1 in total

Review 1.  Clinical Management of Prostate Cancer in High-Risk Genetic Mutation Carriers.

Authors:  Roderick Clark; Jaime Herrera-Caceres; Miran Kenk; Neil Fleshner
Journal:  Cancers (Basel)       Date:  2022-02-16       Impact factor: 6.639
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.